Timothy Gertsch - Sep 11, 2023 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Accounting Officer
Signature
/s/ Mimi Yang, as Attorney-in-Fact
Stock symbol
AGL
Transactions as of
Sep 11, 2023
Transactions value $
-$291,916
Form type
4
Date filed
9/13/2023, 06:03 PM
Previous filing
Aug 18, 2023
Next filing
Apr 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Options Exercise $157K +17.5K +102.21% $8.99 34.6K Sep 11, 2023 Direct F1
transaction AGL Common Stock Sale -$326K -17.5K -50.55% $18.62 17.1K Sep 11, 2023 Direct F1, F2
transaction AGL Common Stock Options Exercise $39.4K +8.75K +51.11% $4.50* 25.9K Sep 11, 2023 Direct F1
transaction AGL Common Stock Sale -$163K -8.75K -33.82% $18.61 17.1K Sep 11, 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Rights to Buy) Options Exercise $0 -17.5K -66.67% $0.00 8.75K Sep 11, 2023 Common Stock 17.5K $8.99 Direct F4
transaction AGL Options (Rights to Buy) Options Exercise $0 -8.75K -50% $0.00 8.75K Sep 11, 2023 Common Stock 8.75K $4.50 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes restricted stock units.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.61 to $18.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.60 to $18.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 These options were granted on July 29, 2020, and became vested as of June 29, 2022 and June 29, 2023.
F5 These options were granted on July 29, 2020, and became vested as of June 29, 2023.